
Alessandro Dal Maso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8973380/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	First-Line Osimertinib in Patients with <i>EGFR</i> -Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study. Oncologist, 2022, 27, 87-e115.	1.9	25
2	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. European Journal of Cancer, 2022, 167, 142-148.	1.3	32
3	Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. Translational Lung Cancer Research, 2021, 10, 202-220.	1.3	29
4	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. Future Oncology, 2021, 17, 2513-2527.	1.1	7
5	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer, 2020, 21, 1-14.e3.	1.1	19
6	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1810-1821.	1.3	7
7	1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2) Tj ETQq1	1@ ∂ 8431	.40rgBT /Ove
8	Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2020, 10, 607840.	1.3	10
9	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers, 2020, 12, 1303.	1.7	6
10	Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC): Platelet-to-lymphocyte ratio (PLR) predicts the risk of development and relapse. Annals of Oncology, 2019, 30, ii58-ii59.	0.6	0
11	Circulating biomarkers and risk of immune-related adverse events (irAEs) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and metastatic melanoma (mMel). Annals of Oncology, 2019, 30, v45.	0.6	0
12	Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. Critical Reviews in Oncology/Hematology, 2019, 138, 87-103.	2.0	16
13	Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Oncologist, 2019, 24, 1128-1136.	1.9	156
14	Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC Journal of Clinical Oncology, 2019, 37, e20612-e20612.	0.8	0
15	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. Oncologist, 2018, 23, 1178-1187.	1.9	46